MARKET

VKTX

VKTX

Viking Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.08
-0.09
-1.46%
After Hours: 6.00 -0.08 -1.32% 19:07 05/17 EDT
OPEN
6.17
PREV CLOSE
6.17
HIGH
6.22
LOW
6.05
VOLUME
507.56K
TURNOVER
--
52 WEEK HIGH
10.09
52 WEEK LOW
5.26
MARKET CAP
474.85M
P/E (TTM)
-10.1843
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 6d ago
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat
Zacks.com · 05/07 16:23
Worldwide Non-Alcoholic Steatohepatitis (NASH) Biomarker Industry to 2028 - Increasing Incidence Rate of Metabolic Comorbidities is Driving Growth
DUBLIN, May 6, 2021 /PRNewswire via COMTEX/ -- DUBLIN, May 6, 2021 /PRNewswire/ -- The "Global Non-Alcoholic Steatohepatitis (NASH) Biomarker Market...
PR Newswire - PRF · 05/06 12:30
Insights on the Non-Alcoholic Steatohepatitis (NASH) Biomarker Global Market to 2028 - by Type, Industry Verticals and Region
Dublin, May 05, May 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Global Non-Alcoholic Steatohepatitis (NASH)...
GlobeNewswire · 05/05 08:43
B.Riley Financial Thinks Viking Therapeutics’ Stock is Going to Recover
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Viking Therapeutics (VKTX) today and set a price target of $15.00. The company's
SmarterAnalyst · 05/04 14:14
Viking Therapeutics (VKTX) Gets a Buy Rating from Maxim Group
Maxim Group analyst Jason McCarthy assigned a Buy rating to Viking Therapeutics (VKTX) yesterday and set a price target of $14.00. The company's shares
SmarterAnalyst · 04/30 14:35
Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer
Oppenheimer analyst Jay Olson maintained a Buy rating on Viking Therapeutics (VKTX) yesterday and set a price target of $12.00. The company's shares
SmarterAnalyst · 04/30 01:35
Viking Therapeutics (VKTX) Received its Third Buy in a Row
SmarterAnalyst · 04/29 13:27
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VKTX. Analyze the recent business situations of Viking Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VKTX stock price target is 19.71 with a high estimate of 40.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 227
Institutional Holdings: 43.90M
% Owned: 56.21%
Shares Outstanding: 78.10M
TypeInstitutionsShares
Increased
43
2.80M
New
20
225.83K
Decreased
48
2.52M
Sold Out
17
2.33M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Non-Executive Chairman/Independent Director
Lawson Macartney
President/Chief Executive Officer/Director
Brian Lian
Chief Financial Officer/IR Contact Officer
Greg Zante
Senior Vice President
Amy Broidrick
Chief Operating Officer
Marianne Mancini
Director
Matthew Foehr
Vice President - Finance/Vice President - Operations
Gregory Zante
Vice President
Catherine Kelleher
Independent Director
S. Kathy Rouan
Independent Director
Charles Rowland
Independent Director
Matthew Singleton
Independent Director
J. Matthew Singleton
No Data
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Webull offers kinds of Viking Therapeutics Inc stock information, including NASDAQ:VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.